What are you looking for today?

Mehmood, Harris, Alowami, Moaz, Hlaing, Thel Su, Zaya, Khant Nyi, Uraiby, Yousrah, Alam, Ahmed Muaaz, Adala, Abubakr, Ikram, Osama, Ali, Syed Faisal, Farhan, Muzammil, Zulfiqar, Eeshal, Ahmed, Mushood, Ahmed, Raheel and Naeem, Ammara (2025) Once‐Weekly Insulin Efsitora Alfa Versus Once Daily Insulin in Patients With Type 2 Diabetes: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 8 (6): e70126. e70126. ISSN 2398-9238

Document

Abstract

Abstract

Background: Once‐daily basal insulin is widely used in the management of type 2 diabetes, but poor adherence to daily injections often impairs glycaemic control. Once‐weekly efsitora alfa may overcome these limitations, but pooled data assessing its comparative efficacy and safety remain limited. Methods: PubMed/MEDLINE, Google Scholar, and the Cochrane Library were searched up to July 2025 for RCTs comparing once‐weekly efsitora with once daily insulin in adults with T2D. Weighted mean differences (MDs), odds ratios (ORs), and risk ratios (RRs) were pooled using a random‐effects model, and results were reported with 95% confidence intervals. Results: Six RCTs comprising 3967 participants were included. There were no significant differences between once‐weekly efsitora and daily insulin in change in HbA1c (MD –0.04; 95% CI –0.10 to 0.02; p = 0.15), change in fasting plasma glucose (MD 1.94 mg/dL; 95% CI –2.98 to 6.86; p = 0.44), proportion of patients achieving HbA1c < 7%, change in body weight, or time below range. Efsitora was associated with an increase in time in range (MD 0.80 percentage points; 95% CI 0.09 to 1.52; p = 0.03) and a reduction in time above range (MD –1.45 percentage points; 95% CI –2.87 to −0.02; p = 0.05). The risk of treatment‐emergent adverse events (TEAEs) was higher with efsitora (RR 1.13; 95% CI 1.05 to 1.20; p = 0.0004), whereas serious adverse events, hypersensitivity reactions, injection‐site reactions, and hypoglycaemia events were comparable between the two groups. Conclusion: Once‐weekly efsitora provides comparable glycaemic control and improved time‐in‐range compared to daily insulin, although with a higher rate of TEAEs.

Item Type: Article
Additional Information: ** Article version: VoR ** From Wiley via Jisc Publications Router ** History: received 03-09-2025; rev-recd 08-10-2025; accepted 14-10-2025; epub 28-10-2025; ppub 01-11-2025. ** Licence for VoR version of this article: http://creativecommons.org/licenses/by/4.0/
Uncontrolled Keywords: basal insulin Fc, daily basal insulin, diabetes, type‐2 diabetes, weekly insulin, efsitora
Related URLs:
SWORD Depositor: Publication Router
Depositing User: Publication Router
URI: https://sure.sunderland.ac.uk/id/eprint/19611

Further Details

More Information

Additional Information
** Article version: VoR ** From Wiley via Jisc Publications Router ** History: received 03-09-2025; rev-recd 08-10-2025; accepted 14-10-2025; epub 28-10-2025; ppub 01-11-2025. ** Licence for VoR version of this article: http://creativecommons.org/licenses/by/4.0/
Uncontrolled Keywords
basal insulin Fc, daily basal insulin, diabetes, type‐2 diabetes, weekly insulin, efsitora
SWORD Depositor
Depositing User

Identifiers

Item ID
19611
Identification Number
ISSN
2398-9238

Users with ORCIDS

ORCID for Mushood Ahmed

Catalogue record

Date Deposited
10 Nov 2025 15:52
Last Modified
10 Nov 2025 15:52

Contributors

Author
Harris Mehmood
Author
Moaz Alowami
Author
Thel Su Hlaing
Author
Khant Nyi Zaya
Author
Yousrah Uraiby
Author
Ahmed Muaaz Alam
Author
Abubakr Adala
Author
Osama Ikram
Author
Syed Faisal Ali
Author
Muzammil Farhan
Author
Eeshal Zulfiqar
Author
Raheel Ahmed
Author
Ammara Naeem

University Divisions

Subjects

Actions (login required)

View Item (Repository Staff Only)

Downloads per month over past year